O-To The Moon - Tiger Brokers Online Investing Community - To The Moon

1
1
Favorite

Zivcheah
2023-01-09

O

CinCor Stock Soars 150% As AstraZeneca Set to Acquire It in up to $1.8B Deal

AstraZeneca (NASDAQ:AZN) is acquiring Waltham, Ma.-based high blood pressure and kidney disease drug

CinCor Stock Soars 150% As AstraZeneca Set to Acquire It in up to $1.8B Deal

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

1

Report

Comment（1）

Top
Latest

Zivcheah
·2023-01-09
O
Reply
Like
Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":9953218475,"tweetId":"9953218475","gmtCreate":1673265268697,"gmtModify":1676538807882,"author":{"id":3582538202393061,"idStr":"3582538202393061","authorId":3582538202393061,"authorIdStr":"3582538202393061","name":"Zivcheah","avatar":"https://static.tigerbbs.com/d52882be9b594ebb5b5933851792d286","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":20,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>O</p></body></html>","htmlText":"<html><head></head><body><p>O</p></body></html>","text":"O","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9953218475","repostId":1118893847,"repostType":4,"repost":{"id":"1118893847","kind":"news","pubTimestamp":1673256357,"share":"https://www.laohu8.com/m/news/1118893847?lang=&edition=full","pubTime":"2023-01-09 17:25","market":"us","language":"en","title":"CinCor Stock Soars 150% As AstraZeneca Set to Acquire It in up to $1.8B Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1118893847","media":"Seeking Alpha","summary":"AstraZeneca (NASDAQ:AZN) is acquiring Waltham, Ma.-based high blood pressure and kidney disease drug","content":"<html><head></head><body><p>AstraZeneca (NASDAQ:AZN) is acquiring Waltham, Ma.-based high blood pressure and kidney disease drug developer CinCor Pharma (NASDAQ:CINC) in a deal value of up to $1.8B.</p><p><img src=\"https://static.tigerbbs.com/527c86ef259063b3cac93c4fb3d881c2\" tg-width=\"857\" tg-height=\"834\" referrerpolicy=\"no-referrer\"/></p><p>The British pharma giant said that the acquisition willbolster its cardiorenal pipeline by adding CinCor&#39;s drug baxdrostat (CIN-107) for blood pressure lowering in treatment-resistant hypertension.</p><p>Under the agreement, AstraZeneca will start a tender offer to acquire all of CinCor&#39;s outstanding shares for $26 per share in cash at closing, plus a non-tradable contingent value right of $10 per share in cash payable upon a specified regulatory submission of a baxdrostat product.</p><p>The upfront cash part of the consideration represents a transaction value of approximately $1.3B. Combined, the upfront and maximum potential contingent value payments represent, if achieved, a transaction value of $1.8B.</p><p>AstraZeneca added that it will acquire the cash and marketable securities on CinCor&#39;s balance sheet, which totaled ~$522M as of Sept. 30, 2022.</p><p>AstraZeneca said baxdrostat represents a potentially leading next-generation aldosterone synthase inhibitor (ASI).</p><p>&#34;Acquiring CinCor supports our commitment to cardiorenal disease and further strengthens our pipeline with baxdrostat. Excess levels of aldosterone are associated with hypertension and several cardiorenal diseases, including chronic kidney disease and coronary artery disease and being able to effectively reduce this would offer a much-needed treatment option for these patients,&#34; said Mene Pangalos, executive vice president BioPharmaceuticals R&amp;D, AstraZeneca.</p><p>CinCor said stockholders holding about 44.8% of CinCor common stock have entered into an agreement with AstraZeneca to tender 100% of their shares in the tender offer.</p><p>The acquisition is expected to close in the Q1 2023, subject to conditions, including U.S. antitrust clearance, and tender of shares of CinCor representing at least a majority of the total number of outstanding shares.</p></body></html>","source":"seekingalpha_fund","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CinCor Stock Soars 150% As AstraZeneca Set to Acquire It in up to $1.8B Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCinCor Stock Soars 150% As AstraZeneca Set to Acquire It in up to $1.8B Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-01-09 17:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3922853-cincor-stock-soars-as-astrazeneca-set-to-acquire-it-in-up-to-18b-deal><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AstraZeneca (NASDAQ:AZN) is acquiring Waltham, Ma.-based high blood pressure and kidney disease drug developer CinCor Pharma (NASDAQ:CINC) in a deal value of up to $1.8B.The British pharma giant said ...</p>\n\n<a href=\"https://seekingalpha.com/news/3922853-cincor-stock-soars-as-astrazeneca-set-to-acquire-it-in-up-to-18b-deal\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","CINC":"CinCor Pharma, Inc."},"source_url":"https://seekingalpha.com/news/3922853-cincor-stock-soars-as-astrazeneca-set-to-acquire-it-in-up-to-18b-deal","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118893847","content_text":"AstraZeneca (NASDAQ:AZN) is acquiring Waltham, Ma.-based high blood pressure and kidney disease drug developer CinCor Pharma (NASDAQ:CINC) in a deal value of up to $1.8B.The British pharma giant said that the acquisition willbolster its cardiorenal pipeline by adding CinCor's drug baxdrostat (CIN-107) for blood pressure lowering in treatment-resistant hypertension.Under the agreement, AstraZeneca will start a tender offer to acquire all of CinCor's outstanding shares for $26 per share in cash at closing, plus a non-tradable contingent value right of $10 per share in cash payable upon a specified regulatory submission of a baxdrostat product.The upfront cash part of the consideration represents a transaction value of approximately $1.3B. Combined, the upfront and maximum potential contingent value payments represent, if achieved, a transaction value of $1.8B.AstraZeneca added that it will acquire the cash and marketable securities on CinCor's balance sheet, which totaled ~$522M as of Sept. 30, 2022.AstraZeneca said baxdrostat represents a potentially leading next-generation aldosterone synthase inhibitor (ASI).\"Acquiring CinCor supports our commitment to cardiorenal disease and further strengthens our pipeline with baxdrostat. Excess levels of aldosterone are associated with hypertension and several cardiorenal diseases, including chronic kidney disease and coronary artery disease and being able to effectively reduce this would offer a much-needed treatment option for these patients,\" said Mene Pangalos, executive vice president BioPharmaceuticals R&D, AstraZeneca.CinCor said stockholders holding about 44.8% of CinCor common stock have entered into an agreement with AstraZeneca to tender 100% of their shares in the tender offer.The acquisition is expected to close in the Q1 2023, subject to conditions, including U.S. antitrust clearance, and tender of shares of CinCor representing at least a majority of the total number of outstanding shares.","news_type":1},"isVote":1,"tweetType":1,"viewCount":495,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":105505798,"commentId":"105505798","gmtCreate":1673265274080,"gmtModify":1673265287110,"authorId":3582538202393061,"author":{"id":3582538202393061,"idStr":"3582538202393061","authorId":3582538202393061,"name":"Zivcheah","avatar":"https://static.tigerbbs.com/d52882be9b594ebb5b5933851792d286","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9953218475,"objectIdStr":"9953218475","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"<u>O</u>","text":"<u>O</u>","html":"<u>O</u>","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}